(Q33584173)

28 July 2017

title

Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data (English)

1 reference

28 July 2017

1 reference

A Vitry

2

0 references

author name string

M J Sorich

1

1 reference

28 July 2017

M B Ward

3

1 reference

28 July 2017

J D Horowitz

4

1 reference

28 July 2017

R A McKinnon

5

1 reference

28 July 2017

publication date

21 May 2010

1 reference

Journal of Thrombosis and Haemostasis

28 July 2017

published in

1 reference

28 July 2017

volume

8

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

1678-1684

1 reference

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Quantifying errors without random sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03923.X

10.1111/J.1538-7836.2010.03923.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference